Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021

HomeTerumo CorporationTerumo and UMCU Strengthen their Partnership to Develop Solutions in Interventional Oncology

Terumo and UMCU Strengthen their Partnership to Develop Solutions in Interventional Oncology

Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successfully collaborated in technology transfer, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Transarterial radioembolization, TARE) for the treatment of unresectable liver tumors.

The MoU marks the continuation of the existing partnership and confirms the shared interest of both parties to enhance education and innovations to develop meaningful solutions that provide significant clinical benefits to patients with cancer and increase their access to treatments.

Quirem Medical, a wholly owned subsidiary of Terumo since July 2020,  based in Deventer, originated as a spin-off from the UMC Utrecht in 2013. Quirem Medical manufactures QuiremSpheres™, the only commercially available microspheres containing the radioactive isotope Holmium-166. Trials have shown the safety and efficacy of holmium microspheres in the treatment of unresectable liver tumors. Quirem Medical also manufactures the SIRT work-up product QuiremScout™ Holmium-166 Microspheres, which is used prior to the therapy to select patients and plan the SIRT procedure. Across Europe, hundreds of patients are treated with QuiremSpheres™ Holmium-166 Microspheres and QuiremScout™ Holmium-166 Microspheres every year.

With the acquisition of Quirem Medical in 2020 and the creation of the Global TIO team in 2021, we see great opportunities to leverage the broad Terumo technology base in interventional oncology for improved cancer care. The UMC Utrecht has proven a highly reliable, professional & innovative clinical partner with a strong focus on image guided therapies in cancer care. As such, the UMC Utrecht is a partner of choice in this journey; and we look forward to a successful continuation of our close collaboration in education, innovation and data generation to contribute to society through healthcare together.” Says Ghada Farah, Senior Vice President Terumo Interventional Systems EMEA.

Terumo, a global leader in medical technology, announced on April 12, 2021 the launch of its Global Therapeutic Interventional Oncology (TIO) team. This reflects Terumo’s aspiration to be a global leader in the field of Interventional Oncology by focusing on improving patient’s quality of life and survival.

“Terumo and the UMC Utrecht have a fruitful history of collaboration on QuiremSpheres™ Holmium-166 Microspheres for radioembolization of liver tumors. This Memorandum of Understanding underlines the collaboration that is already there for QuiremSpheres™ Holmium-166 Microspheres and the ambition to collaborate in the broader range of interventional oncology, including tumor ablation and chemoembolization. Terumo’s dedication to improve patient care and the company’s global reach make Terumo an ideal partner for this journey.” says Dr. Maarten Smits, Interventional Radiologist, UMC Utrecht

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy